News
Technology for improved cancer patient outcomes
9 Jun 2023
Cambridge partners with the University of Strathclyde to develop ‘Digital twins’ – exact computer models of patients – to enhance cancer patients’ recovery times following surgery.
Junior Investigators attend Leicester meeting
8 Feb 2023
Annual Junior Investigators Network Group meeting held in Leicester on 6 and 7 Feb 2023
New hope for kidney cancer using existing drugs
23 Nov 2022
Cambridge researchers have discovered that a drug given to lung cancer patients could be used to treat renal cell carcinoma, a cancer with a high mortality rate that is hard to detect.
Prostate cancer cases risk late detection due to misleading urinary focus
4 Aug 2022
A review by Cambridge researchers argues that not only is this unhelpful, but it may even deter men from coming forward for early testing and detection of a potentially treatable cancer.
Home in a day after robotic prostate cancer surgery
29 Jul 2022
A surgical robot at Addenbrooke’s is helping to cure patients with prostate cancer, enabling them to go home less than 24 hours after surgery.
Review of kidney cancer management
26 Jul 2022
Urological Malignancies Programme Co-lead Professor Grant Stewart authors seminal review of kidney cancer management.
Research reveals how genetic mutations cause kidney cancer
8 Jun 2022
A study has identified how common genetic alterations lead to the development of kidney cancer.
Yorkshire Kidney Screening Trial recruitment success
30 Mar 2022
A trial led by Prof Grant Stewart and Dr Juliet Usher-Smith is assessing the feasibility of scanning the kidneys as well as the lungs to detect early signs of cancer.
Cancer and Artificial Intelligence Podcast
11 Feb 2022
Researchers from the Mark Foundation Institute for Integrated Cancer Medicine discuss how artificial intelligence is making it easier for doctors to diagnose and treat cancer.
Faulty BRCA genes linked to prostate and pancreatic cancers
25 Jan 2022
Faulty versions of the BRCA1 and BRCA2 genes are well known to increase the risk of breast cancer in men and women, and in ovarian cancer. Now BRCA1 and BRCA2 have been linked to several other cancers, including those that affect men.